| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Khatijah Binti Mohamad Yusoff | Q31331439 |
| Abdul Rahman Omar | Q61159465 | ||
| Swee Yeap | Q38799034 | ||
| P2093 | author name string | Noorjahan Banu Alitheen | |
| Mehdi R Pirozyan | |||
| Suraini Abd-Aziz | |||
| Han Yuen Lam | |||
| Abd Aziz Suraini | |||
| P2860 | cites work | Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses | Q24631361 |
| A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8 T cell repertoire | Q24654139 | ||
| p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines | Q24672443 | ||
| Dr William Coley and tumour regression: a place in history or in the future | Q24680367 | ||
| Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. | Q33184415 | ||
| A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization | Q33370984 | ||
| Natural killer cells in antiviral defense: function and regulation by innate cytokines | Q33652468 | ||
| Viruses in the treatment of cancer | Q34201994 | ||
| An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 | ||
| A summary of taxonomic changes recently approved by ICTV. | Q34526294 | ||
| Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines | Q34648125 | ||
| Two ways to induce innate immune responses in human PBMCs: paracrine stimulation of IFN-alpha responses by viral protein or dsRNA. | Q51834932 | ||
| Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. | Q51997552 | ||
| In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein. | Q53589526 | ||
| Attenuated veterinary virus vaccine for the treatment of cancer. | Q54055131 | ||
| Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity | Q69055309 | ||
| Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects | Q70030614 | ||
| Tumor vaccination in renal cell carcinoma with and without interleukin-2 (IL-2) as adjuvant. A clinical contribution to the development of effective active specific immunization | Q71876308 | ||
| Antiviral response by natural killer cells through TRAIL gene induction by IFN-alpha/beta | Q77357379 | ||
| Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells | Q45556110 | ||
| Clinical and immunological effects of Newcastle disease virus vaccine on bovine papillomatosis | Q45643316 | ||
| Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen | Q45657370 | ||
| NEWCASTLE DISEASE VIRUS AS AN ANTINEOPLASTIC AGENT. | Q45713156 | ||
| Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. | Q45732157 | ||
| Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers | Q45732737 | ||
| Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration | Q45735369 | ||
| Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. | Q45737842 | ||
| Newcastle disease virus activates macrophages for anti-tumor activity | Q45745054 | ||
| Scientific interest in Newcastle disease virus is reviving | Q45746700 | ||
| Immunization with virus-modified tumor cells. | Q45752163 | ||
| Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma | Q45752822 | ||
| Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy | Q45782480 | ||
| Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines | Q45788946 | ||
| A phase II study on the postsurgical management of Stage II malignant melanoma with a Newcastle disease virus oncolysate | Q45793855 | ||
| Studies on the cytopathic effects of Newcastle disease virus: the cytopathogenicity of strain Herts 33 in five cell types | Q45815112 | ||
| Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity of proteolytic cleavage of an inactive precursor protein of Sendai virus | Q45818684 | ||
| Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation | Q45847458 | ||
| In vitro and clinical characterisation of a newcastle disease virus-modified autologous tumour cell vaccine for treatment of colorectal cancer patients | Q45856337 | ||
| Newcastle disease virus selectively kills human tumor cells | Q45865340 | ||
| Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial | Q45872022 | ||
| A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate | Q45875393 | ||
| Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus | Q34680077 | ||
| New aspects of natural-killer-cell surveillance and therapy of cancer | Q34988265 | ||
| Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens | Q35834369 | ||
| Pathogen recognition with Toll-like receptors | Q36159961 | ||
| Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract | Q36209720 | ||
| FEC (5-fluorouracil-epirubicin-cyclophosphamide) monthly versus FEC weekly in metastatic breast cancer. First results of a randomized trial | Q36286955 | ||
| Macrophage activation: increased ingestion of IgG-coated erythrocytes after administration of interferon inducers to mice | Q36340758 | ||
| Maturation, activation, and protection of dendritic cells induced by double-stranded RNA | Q36367830 | ||
| Use of BCG as an immunostimulant in the surgical treatment of carcinoma of the lung | Q36432705 | ||
| An overview on the development of newcastle disease virus as an anti-cancer therapy. | Q36568040 | ||
| Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus | Q36754449 | ||
| Selective cytotoxicity of goniothalamin against hepatoblastoma HepG2 cells. | Q39562856 | ||
| Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase | Q39839714 | ||
| Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma | Q39927229 | ||
| Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. | Q39936518 | ||
| Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial | Q39980841 | ||
| An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins | Q39999422 | ||
| Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy | Q40072336 | ||
| Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. | Q40072888 | ||
| Effect of Rhaphidophora korthalsii methanol extract on human peripheral blood mononuclear cell (PBMC) proliferation and cytolytic activity toward HepG2. | Q40077962 | ||
| Viral oncolysate in the management of malignant melanoma.I. Preparation of the oncolysate and measurement of immunologic responses | Q40089626 | ||
| Viral oncolysate in the management of malignant melanoma. II. Clinical studies | Q40089633 | ||
| Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence | Q40318115 | ||
| The cytotoxic anti-tumor effect of MTH-68/H, a live attenuated Newcastle disease virus is mediated by the induction of nitric oxide synthesis in rat peritoneal macrophages in vitro | Q40332804 | ||
| Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme | Q40495113 | ||
| Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus | Q40722351 | ||
| Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine | Q40766761 | ||
| Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells | Q40886050 | ||
| Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine. | Q41044825 | ||
| Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus | Q41504382 | ||
| Viral hemagglutinin augments peptide-specific cytotoxic T cell responses | Q41522249 | ||
| Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns | Q41721511 | ||
| Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor-specific cytolytic T cell activity via induction of interferon-alpha/beta | Q43783366 | ||
| EARLY STAGES OF NEWCASTLE DISEASE VIRUS-HELA CELL INTERACTION: AN ELECTRON MICROSCOPIC STUDY. | Q43792587 | ||
| Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B. | Q44069162 | ||
| Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor-cell vaccine. First clinical results with tumor-cell vaccines modified with live but avirulent Newcastle disease virus | Q44271060 | ||
| Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus | Q44438732 | ||
| Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. | Q44550766 | ||
| Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma | Q44685850 | ||
| TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus | Q44935548 | ||
| Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer | Q45071436 | ||
| An optimized clinical regimen for the oncolytic virus PV701. | Q45407407 | ||
| Effects of rate, volume, and dose of intratumoral infusion on virus dissemination in local gene delivery | Q45419376 | ||
| Toll-like receptor 3 promotes cross-priming to virus-infected cells. | Q45511446 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | cancer | Q12078 |
| virus | Q808 | ||
| Newcastle disease virus | Q327082 | ||
| neoplasm | Q1216998 | ||
| cancer vaccine | Q2378309 | ||
| Newcastle disease | Q11903425 | ||
| biomedical investigative technique | Q66648976 | ||
| oncolytic virotherapy | Q73217729 | ||
| P304 | page(s) | 718710 | |
| P577 | publication date | 2011-10-26 | |
| P1433 | published in | Journal of Biomedicine and Biotechnology | Q15752146 |
| P1476 | title | Safety and clinical usage of newcastle disease virus in cancer therapy | |
| P478 | volume | 2011 |
| Q64233021 | Adaptation of the Newcastle Disease Virus to Cell Cultures for Enhancing Its Oncolytic Properties |
| Q38886736 | Antineoplastic activity of Newcastle disease virus strain D90 in oral squamous cell carcinoma |
| Q90924607 | Attenuate Newcastle disease virus by codon modification of the glycoproteins and phosphoprotein genes |
| Q28261383 | Avian Paramyxovirus: A Brief Review |
| Q47553728 | Corrigendum to "Safety and Clinical Usage of Newcastle Disease Virus in Cancer Therapy". |
| Q34318157 | Current status of gene therapy for brain tumors. |
| Q96953244 | Cytotoxicity study of the interleukin-12-expressing recombinant Newcastle disease virus strain, rAF-IL12, towards CT26 colon cancer cells in vitro and in vivo |
| Q94564034 | Delivery and Biosafety of Oncolytic Virotherapy |
| Q59356802 | Designing a Novel Recombinant HN Protein with Multi Neutralizing Antigenic Sites and Auto Tag Removal Ability Based on NDV-VIIj for Diagnosis and Vaccination Application |
| Q36549443 | EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA |
| Q51734249 | Effect of the oncolytic ECHO-7 virus Rigvir® on the viability of cell lines of human origin in vitro. |
| Q35587389 | Enhancement of the proapoptotic properties of newcastle disease virus promotes tumor remission in syngeneic murine cancer models |
| Q38701351 | Evaluation of the oncolytic potential of R2B Mukteshwar vaccine strain of Newcastle disease virus (NDV) in a colon cancer cell line (SW-620). |
| Q64113944 | Fludarabine as an Adjuvant Improves Newcastle Disease Virus-Mediated Antitumor Immunity in Hepatocellular Carcinoma |
| Q38348844 | Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No? |
| Q41168464 | Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion. |
| Q41505946 | Molecular characterization of an apoptotic strain of Newcastle disease virus isolated from an outbreak in India |
| Q41744540 | Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death |
| Q40680375 | Newcastle disease virus chimeras expressing the Hemagglutinin- Neuraminidase protein of mesogenic strain exhibits an enhanced anti-hepatoma efficacy |
| Q92215118 | Newcastle disease virus mediated apoptosis and migration inhibition of human oral cancer cells: A probable role of β-catenin and matrix metalloproteinase-7 |
| Q38192846 | Newcastle disease virus: current status and our understanding |
| Q35861933 | Oncolysis by paramyxoviruses: preclinical and clinical studies. |
| Q38599166 | Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance |
| Q54241184 | Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model. |
| Q47164675 | Pigeon paramyxovirus type 1 from a fatal human case induces pneumonia in experimentally infected cynomolgus macaques (Macaca fascicularis). |
| Q39789912 | Prostate-specific antigen-retargeted recombinant newcastle disease virus for prostate cancer virotherapy |
| Q37133496 | Recombinant Newcastle disease virus expressing P53 demonstrates promising antitumor efficiency in hepatoma model |
| Q92345887 | Syncytia Formation in Oncolytic Virotherapy |
| Q36405474 | The hemagglutinin-neuramidinase protein of Newcastle disease virus upregulates expression of the TRAIL gene in murine natural killer cells through the activation of Syk and NF-κB |
| Q38924554 | Therapeutic potential of oncolytic Newcastle disease virus: a critical review |
| Q40500761 | Transplanted tumor growth and the incidence of T-lymphocyte populations in the spleen of newcastle virus-treated mice. |
| Q92138054 | Tumor Cells Modified with Newcastle Disease Virus Expressing IL-24 as a Cancer Vaccine |
| Q34311097 | Viruses in cancer treatment |
Search more.